Teva Pharmaceutical | StockChase
238
Teva Pharmaceutical (TEVA-N)

Last Price Recorded: $16.5200 on 2017-12-12

ON STOCKCHASE SINCE Dec 2000

Patented and lower price generic drugs

biotechnology/pharmaceutical
238
Teva Pharmaceutical (TEVA-N)

Last Price Recorded: $16.5200 on 2017-12-12

ON STOCKCHASE SINCE Dec 2000

Patented and lower price generic drugs

biotechnology/pharmaceutical

Teva Pharmaceutical


Signal Opinion Expert
DON'T BUY
Teva Pharmaceutical(TEVA-N) 

December 7, 2017

Don’t go near it.  They are looking at mid-20% losses this and next year then flat earnings after that.

biotechnology/pharmaceutical

Don’t go near it.  They are looking at mid-20% losses this and next year then flat earnings after that.

biotechnology/pharmaceutical
Cameron Hurst

Chief Investment Officer, Equium Capital Manag...

PricePrice
$15.000
Owned Owned
Unknown

COMMENT
Teva Pharmaceutical(TEVA-N) 

November 28, 2017

The largest generic drug manufacturer. The FDA and other global drug regulators and governments are so focused on driving down the costs of healthcare, including drugs, there is pressure on the entire generics sector. The company has had many other issues as well.

biotechnology/pharmaceutical

The largest generic drug manufacturer. The FDA and other global drug regulators and governments are so focused on driving down the costs of healthcare, including drugs, there is pressure on the entire generics sector. The company has had many other issues as well.

biotechnology/pharmaceutical
Lorne Steinberg

President & Portfolio Manager, Lorne Steinberg Weal...

PricePrice
$14.690
Owned Owned
No

COMMENT
Teva Pharmaceutical(TEVA-N) 

November 24, 2017

This has fallen a long way. What you have to think about is, should you take a tax loss. If you haven’t done it yet, it might be worthwhile. You can also buy it back after 30 days and you will have crystallized your loss.

biotechnology/pharmaceutical

This has fallen a long way. What you have to think about is, should you take a tax loss. If you haven’t done it yet, it might be worthwhile. You can also buy it back after 30 days and you will have crystallized your loss.

biotechnology/pharmaceutical
Benj Gallander

President, Contra the Heard Inv...

PricePrice
$13.700
Owned Owned
Unknown

DON'T BUY
Teva Pharmaceutical(TEVA-N) 

November 23, 2017

Doesn’t see any Buy signal yet. It looks like it will continue going lower. Let buyers emerge first, before buying this. He would avoid for now.

biotechnology/pharmaceutical

Doesn’t see any Buy signal yet. It looks like it will continue going lower. Let buyers emerge first, before buying this. He would avoid for now.

biotechnology/pharmaceutical
William Chin

Portfolio manager, Caldwell Investment ...

PricePrice
$13.480
Owned Owned
Unknown

PAST TOP PICK
Teva Pharmaceutical(TEVA-N) 

November 22, 2017

(A Top Pick Dec 28/16. Down 61%.) He got out of this 2 months later at about $32, so was down about 10%. Shortly after he bought this, the CEO left for undisclosed reasons, and he took that as a giant warning sign, so he ran away that same day.

biotechnology/pharmaceutical

(A Top Pick Dec 28/16. Down 61%.) He got out of this 2 months later at about $32, so was down about 10%. Shortly after he bought this, the CEO left for undisclosed reasons, and he took that as a giant warning sign, so he ran away that same day.

biotechnology/pharmaceutical
Norman Levine

Managing Director, Portfolio Management...

PricePrice
$13.480
Owned Owned
No

DON'T BUY
Teva Pharmaceutical(TEVA-N) 

November 20, 2017

He has not been in it for a long time.  It is a very competitive space and a few drugs were up against competition.  He has not got excited about it and has not invested in it.

biotechnology/pharmaceutical

He has not been in it for a long time.  It is a very competitive space and a few drugs were up against competition.  He has not got excited about it and has not invested in it.

biotechnology/pharmaceutical
Mark Grammer

Managing Dir. & Portfolio Manager, Gluskin Sheff & Asso...

PricePrice
$13.080
Owned Owned
No

COMMENT
Teva Pharmaceutical(TEVA-N) 

November 13, 2017

Politicians love to hate drug stocks, because they are the most obvious part of the healthcare system and they can badmouth them. As a generic manufacturer, the only cost they have is the pill, and they can drive down the price. As governments globally tried to encourage generic pharmaceuticals, to take pricing pressure off, there was a lot of government support for them. Now that most of the major drug companies have been genericized, they are squeezing them as well. This company consolidated and took on a lot of debt, and are still being squeezed. 7.5% dividend yield.

biotechnology/pharmaceutical

Politicians love to hate drug stocks, because they are the most obvious part of the healthcare system and they can badmouth them. As a generic manufacturer, the only cost they have is the pill, and they can drive down the price. As governments globally tried to encourage generic pharmaceuticals, to take pricing pressure off, there was a lot of government support for them. Now that most of the major drug companies have been genericized, they are squeezing them as well. This company consolidated and took on a lot of debt, and are still being squeezed. 7.5% dividend yield.

biotechnology/pharmaceutical
Bruce Murray

CEO & Chief Investment Officer, The Murray Wealth Gr...

PricePrice
$11.740
Owned Owned
No

COMMENT
Teva Pharmaceutical(TEVA-N) 

November 2, 2017

Sell or hold? A global generic company based in Israel. They've had a couple of CEO's they've gone through. The stock has fallen a lot. A new CEO is coming in, who had really turned around another company. Expects the 8.4% dividend will be cut even more. The generic business has been a lot tougher over the last while. The place to buy this is after they've cut the dividend. It's going to be much more volatile over the next little while.

biotechnology/pharmaceutical

Sell or hold? A global generic company based in Israel. They've had a couple of CEO's they've gone through. The stock has fallen a lot. A new CEO is coming in, who had really turned around another company. Expects the 8.4% dividend will be cut even more. The generic business has been a lot tougher over the last while. The place to buy this is after they've cut the dividend. It's going to be much more volatile over the next little while.

biotechnology/pharmaceutical
Paul Harris, CFA

Portfolio Manager and Partner, Avenue Investment Ma...

PricePrice
$11.230
Owned Owned
Unknown

COMMENT
Teva Pharmaceutical(TEVA-N) 

October 24, 2017

Sell? This has been a disaster. If considering dumping, is this in a taxable account and do you need losses? If you are a long-term investor, this is a really good stock. Ask yourself, “If I didn’t own this, would I buy it today?”. He believes in the long-term thesis of this company, growth in generics. They control about 20% of the global generics drug market. As the global population grows and people get older, are countries like China and others going to care for their citizens? They are going to need generic drugs, because they are going to be significantly cheaper.

biotechnology/pharmaceutical

Sell? This has been a disaster. If considering dumping, is this in a taxable account and do you need losses? If you are a long-term investor, this is a really good stock. Ask yourself, “If I didn’t own this, would I buy it today?”. He believes in the long-term thesis of this company, growth in generics. They control about 20% of the global generics drug market. As the global population grows and people get older, are countries like China and others going to care for their citizens? They are going to need generic drugs, because they are going to be significantly cheaper.

biotechnology/pharmaceutical
John Petrides

Managing Dir. & Portfolio Manager, Point View Wealth Ma...

PricePrice
$14.280
Owned Owned
Unknown

COMMENT
Teva Pharmaceutical(TEVA-N) 

October 24, 2017

Stayed away from this because of the balance sheet. They ran into issues with their covenants. On the debt side they borrowed a significant amount of money to buy Octavis’ generic business. The income was less than expected because of deterioration in the pricing of generic drugs. About half the company’s operating profit was coming from Copaxone for MS, and the competition was able to invalidate the patent on the 3X a week dosage, and was able to take some share.

biotechnology/pharmaceutical

Stayed away from this because of the balance sheet. They ran into issues with their covenants. On the debt side they borrowed a significant amount of money to buy Octavis’ generic business. The income was less than expected because of deterioration in the pricing of generic drugs. About half the company’s operating profit was coming from Copaxone for MS, and the competition was able to invalidate the patent on the 3X a week dosage, and was able to take some share.

biotechnology/pharmaceutical
David Fingold

VP and Portfolio Manager, Dynamic Funds...

PricePrice
$14.280
Owned Owned
No

DON'T BUY
Teva Pharmaceutical(TEVA-N) 

October 13, 2017

Had a really tough go. They’ve been good operators but made some acquisitions where some of the products got price squeezes. Also Mylan (MYL-Q) recently put out a drug for multiple sclerosis which got approved. It is a generic version of Teva’s non-generic version. There’s too much risk.

biotechnology/pharmaceutical

Had a really tough go. They’ve been good operators but made some acquisitions where some of the products got price squeezes. Also Mylan (MYL-Q) recently put out a drug for multiple sclerosis which got approved. It is a generic version of Teva’s non-generic version. There’s too much risk.

biotechnology/pharmaceutical
Matt Kacur

President, FSA Financial Scienc...

PricePrice
$14.980
Owned Owned
Unknown

DON'T BUY
Teva Pharmaceutical(TEVA-N) 

September 29, 2017

Some of the larger pharmaceutical stocks can do quite well during the 4th quarter. Not sure this company falls into that category, but it does follow that same seasonal timeline. A Buy date of Oct 20 and a Sell date of March 10, has produced a 5.92% average return above the markets, and has been positive 15 out of the past 20 periods. There is a period of seasonal strength coming ahead, but looking at the technicals, do you really want to enter now when it is probably not ideal. The chart shows a series of lower highs and lower lows. It had a gap in August. Whenever you have a gap, it indicates support or resistance on the retracement. Not a good time to be in this, and he would stay away.

biotechnology/pharmaceutical

Some of the larger pharmaceutical stocks can do quite well during the 4th quarter. Not sure this company falls into that category, but it does follow that same seasonal timeline. A Buy date of Oct 20 and a Sell date of March 10, has produced a 5.92% average return above the markets, and has been positive 15 out of the past 20 periods. There is a period of seasonal strength coming ahead, but looking at the technicals, do you really want to enter now when it is probably not ideal. The chart shows a series of lower highs and lower lows. It had a gap in August. Whenever you have a gap, it indicates support or resistance on the retracement. Not a good time to be in this, and he would stay away.

biotechnology/pharmaceutical
Jon Vialoux

Research Analyst, Timingthemarket.ca &...

PricePrice
$17.600
Owned Owned
Unknown

WAIT
Teva Pharmaceutical(TEVA-N) 

September 14, 2017

He got in in January.  It was hard to make that decision.  He sold because the outlook on generic drug prices became weak (down 8-10%).  A new CEO came in recently.  He does not like their business and does not know if it will decline further.  Wait and see if there is recovery.

biotechnology/pharmaceutical

He got in in January.  It was hard to make that decision.  He sold because the outlook on generic drug prices became weak (down 8-10%).  A new CEO came in recently.  He does not like their business and does not know if it will decline further.  Wait and see if there is recovery.

biotechnology/pharmaceutical
Paul Macdonald

Chief Investment Officer & Portfolio Manager, Harvest Portfolios G...

PricePrice
$18.360
Owned Owned
No

SELL
Teva Pharmaceutical(TEVA-N) 

September 12, 2017

There is a long road for new management. A lot to do and very significant fundamental risks. There are a number of well-flagged horrendously long list of knocks against the company right now. It has recently had a nice upswing, so if you own it, lock it in and walk away.

biotechnology/pharmaceutical

There is a long road for new management. A lot to do and very significant fundamental risks. There are a number of well-flagged horrendously long list of knocks against the company right now. It has recently had a nice upswing, so if you own it, lock it in and walk away.

biotechnology/pharmaceutical
Cameron Hurst

Chief Investment Officer, Equium Capital Manag...

PricePrice
$19.330
Owned Owned
Unknown

DON'T BUY
Teva Pharmaceutical(TEVA-N) 

September 7, 2017

This became the largest generic drug manufacturer globally. Then they changed their business model because they wanted to get into making branded pharmaceuticals, and that has been a disaster. At the same time, they took on a huge amount of debt to make acquisitions, which he was not hugely crazy about. Generics are now under the same types of pressures as branded pharmaceuticals. They simply have way too much debt. Not the kind of business you want to be in.

biotechnology/pharmaceutical

This became the largest generic drug manufacturer globally. Then they changed their business model because they wanted to get into making branded pharmaceuticals, and that has been a disaster. At the same time, they took on a huge amount of debt to make acquisitions, which he was not hugely crazy about. Generics are now under the same types of pressures as branded pharmaceuticals. They simply have way too much debt. Not the kind of business you want to be in.

biotechnology/pharmaceutical
Lorne Steinberg

President & Portfolio Manager, Lorne Steinberg Weal...

PricePrice
$15.470
Owned Owned
No

Showing 1 to 15 of 238 entries
<< < 1 2 3 4 5 > >>

No Comments.


You must be logged in to comment.

Successfully Saved Company